临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 65-86-1

Orotic acid (6-Carboxyuracil)

中文名称:乳清酸
CAS号:65-86-1
分子式: C5H4N2O4 分子量: 156.10
产品形式: free base
研发状态: Completed
研发用途: Hereditary Orotic Aciduria
研究机构: Wellstat Therapeutics
研发日期: Apr-14
研发阶段: Phase 3
Orotic acid(6-Carboxyuracil) is a heterocyclic compound and an acid.

CAS: 657-24-9

Metformin

中文名称:二甲双胍
CAS号:657-24-9
分子式: C4H11N5 分子量: 129.16
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Sarcoidosis Pulmonary
研究机构: University of Maryland Baltimore
研发日期: May 1 2024
研发阶段: Phase 2
Metformin (1,1-Dimethylbiguanide), a widely used drug for treatment of type 2 diabetes, activates AMP-activated protein kinase (AMPK) in hepatocytes. Metformin promotes mitophagy in mononuclear cells. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153.

CAS: 65710-07-8

Apramycin Sulfate

中文名称:硫酸阿布拉霉素
CAS号:65710-07-8
分子式: C21H41N5O11.xH2SO4 分子量: 637.66
产品形式: Sulfate
研发状态: Recruiting
研发用途: Bacterial Infection
研究机构: National Institute of Allergy and Infectious Diseases (NIAID)
研发日期: June 16 2023
研发阶段: Phase 1
Apramycin Sulfate (Ai3-29795) is an aminoglycoside antibiotic, which binds to the deep groove of the RNA.

CAS: 65666-07-1

Silymarin

中文名称:水飞蓟素
CAS号:65666-07-1
分子式: C25H22O10 分子量: 482.44
产品形式: free base
研发状态: Unknown status
研发用途: Melasma
研究机构: Assiut University
研发日期: May-22
研发阶段: Phase 4
Silymarin (Silybin B), a polyphenolic flavonoid extracted from the seeds of Silybum marianum or milk thistle, is used in the prevention and treatment of liver diseases and primary liver cancer.

CAS: 65646-68-6

Fenretinide (NSC 374551)

中文名称:芬维A胺
CAS号:65646-68-6
分子式: C26H33NO2 分子量: 391.55
产品形式: free base
研发状态: Recruiting
研发用途: T-cell Lymphoma; Cutaneous/Peripheral T-Cell Lymphoma; Peripheral T-cell Lymphoma; Peripheral T-Cell Lymphoma Not Classified; Primary Cutaneous T-cell Lymphoma; Cutaneous T-Cell Lymphoma Unspecified; Cutaneous T-cell Lymphoma; Follicular T-Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Sézary''s Disease; Mycosis Fungoides
研究机构: SciTech Development LLC
研发日期: December 18 2023
研发阶段: Phase 1
Fenretinide (4-hydroxy(phenyl)retinamide, 4-HPR, MK-4016) is a synthetic derivative of retinoic acid that has a broad-spectrum of cytotoxic activity against primary tumor cells, cell lines, and/or xenografts of various cancers (including neuroblastoma). Fenretinide (4-hydroxy(phenyl)retinamide; 4-HPR) is a synthetic derivative of retinoic acid, fenretinide can bind to retinoic acid receptor (RAR) and retinoid X receptor (RXR) at concentrations necessary to induce cell death.

CAS: 656247-18-6

Nintedanib Ethanesulfonate Salt

中文名称:尼达尼布乙基磺酸盐
CAS号:656247-18-6
分子式: C31H33N5O4.C2H6O3S 分子量: 649.76
产品形式: ethanesulfonate
研发状态: Recruiting
研发用途: Idiopathic Pulmonary Fibrosis; Diarrhoea
研究机构: Boehringer Ingelheim
研发日期: April 30 2024
研发阶段: --
Nintedanib (Intedanib, BIBF 1120) is a small molecule tyrosine-kinase inhibitor with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β, respectively.